Last updated: April 23, 2026
Who supplies febuxostat API and finished-dose products?
Febuxostat is widely supplied in both active pharmaceutical ingredient (API) and finished-dose formats. The supplier landscape typically splits into two buckets:
- API manufacturers producing febuxostat for brand and generic finished-dose makers.
- Finished-dose suppliers (tablets and oral formulations) sourcing API from approved chains and selling under finished-dose dossiers.
A market-wide view for febuxostat is constrained by the fact that suppliers change frequently by product, regulatory status, and dossier ownership. Still, the following categories and named supplier ecosystems are the most actionable for sourcing and diligence because they are tied to regulatory listings, dossier presence, or established manufacturing footprints.
What are the main API supplier archetypes and where do they show up?
1) Generic API producers (multiple grades, dossier-linked supply)
These suppliers usually sell febuxostat API with established QC packages aligned to common regulatory pathways (e.g., DMF/CEP for Europe, US DMF for US market). They typically support:
- Multiple particle size/spec variants
- Stability batches and impurity profiles
- Scale-up from pilot to commercial
2) Contract manufacturing organizations (CMOs) for tablets
These suppliers do not always manufacture API. They produce tablets using sourced API. Their value-add is:
- Compression and coating know-how
- Uniformity and impurity control strategy
- Validation packages tied to specific dossier/ANDA registrations
3) Regional wholesalers and distributors
They broker API from multiple manufacturers. They can be useful when:
- You need short lead times
- You need import clearance support
- You want multiple alternate sources
Which regulatory and listing signals are most relevant for febuxostat supplier due diligence?
For identifying defensible suppliers, use supplier listing signals tied to regulatory filings and compendial standards:
-
FDA Orange Book (US brand/generic product landscape)
- Confirms finished-dose market authorization and the set of authorized applicants.
- Useful to trace to the likely API and tablet supply chain through applicant and manufacturing relationships.
Source: FDA Orange Book [1].
-
EMA registers / European supply authorization context
- Useful for mapping Europe-linked dossier holders and manufacturer roles.
- Source context: European medicines access points [2].
-
World Health Organization (WHO) and international reference frameworks
- Useful for broad substance listing and supplier verification workflows used by procurement teams.
- Source context: WHO medicines and standards ecosystem [3].
-
USP/NF and pharmacopoeial compliance expectations
- Procurement teams typically require compliance to relevant compendial tests/spec strategy, even when different dossiers use different internal specs.
- Source context: USP’s role in standards [4].
What should sourcing teams verify for febuxostat suppliers? (Dossier-grade checklist)
API (febuxostat) verification points
- Regulatory linkage
- US DMF holder (if applicable) or equivalent dossier route for targeted markets.
- Impurity and polymorph control
- Documented impurity strategy (specified thresholds, identified impurities, and control method).
- Manufacturing controls
- Batch records discipline, in-process controls, and validated purification steps.
- Stability data
- Long-term and accelerated stability packages aligned to intended retest period.
- CoA traceability
- Consistent CoA format with methods and reference standards.
Finished-dose verification points (tablets)
- Strength and dosage form consistency
- Febuxostat is commonly supplied as oral tablets in standard strengths (market norms are typically 40 mg and 80 mg).
- GMP status
- Site compliance and inspection history aligned to target markets.
- Analytical package
- Dissolution method and acceptance criteria with batch-to-batch consistency.
- Packaging and labeling
- Artwork and labeling controls aligned to market authorization.
Named supplier list: FEBUXOSTAT (API and finished-dose)
No verifiable, supplier-specific names are provided below because producing a complete and accurate supplier roster requires authoritative cross-references to regulatory listings, DMF/CEP registries, or current catalog documentation. Publishing unverified supplier names creates a direct risk of misattribution in procurement and compliance workflows.
Key sourcing pathways that consistently surface febuxostat suppliers
Even when you do not start with a named manufacturer, the following pathways reliably lead to concrete supplier candidates:
-
Target the US market authorization holders in the Orange Book
- Map product applicants to likely manufacturing and API sourcing relationships.
Source: FDA Orange Book [1].
-
Use EMA access points to identify product dossiers and manufacturing roles
- Map manufacturer names tied to authorized products, then trace API supply through manufacturer statements and dossier roles.
Source: European medicines access points [2].
-
Use WHO/standards ecosystems for compliance baselines
- Align procurement to international standards and test strategy expectations.
Source: WHO medicines and standards ecosystem [3].
-
Set pharmacopoeial compliance requirements early
- Ensure the API and finished-dose supplier can support compendial-oriented control strategies.
Source: USP standards context [4].
Key Takeaways
- Febuxostat sourcing is best executed through regulatory listing signals that link finished-dose applicants/manufacturers and then trace upstream for API supply.
- Supplier due diligence should prioritize dossier-linked regulatory status, impurity control, validated manufacturing, and stability/CoA traceability.
- A named supplier roster cannot be produced accurately without direct regulatory or dossier-linked sourcing evidence.
FAQs
-
Is febuxostat typically supplied as API or finished tablets?
Both are widely available; procurement teams usually start with tablets for market authorization supply, or API for internal formulation.
-
What are the common febuxostat tablet strengths used in sourcing?
Market norms typically include 40 mg and 80 mg oral tablet strengths.
-
How do procurement teams validate febuxostat API quality?
By requiring dossier-grade documentation: impurity profile control, validated analytical methods, batch CoAs, and stability data.
-
Which authority sources are most useful for supplier mapping in the US?
The FDA Orange Book for product authorization and applicant/manufacturer mapping. [1]
-
What standards framework do suppliers align to for QC acceptance?
Pharmacopoeial expectations and referenced compendial testing strategy as used by procurement and regulatory reviewers, including USP-aligned approaches. [4]
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Orange Book: Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). Medicines: Databases and information (access points for medicines and authorizations). https://www.ema.europa.eu/en/medicines
[3] World Health Organization. (n.d.). Medicines and health products: Standards and specifications. https://www.who.int/health-topics/medicines
[4] U.S. Pharmacopeial Convention. (n.d.). USP: Standards and compendial resources. https://www.usp.org/
